Inex/Enzon's Marqibo Not Eligible For Accelerated Approval, Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Treatments described in literature constitute "available therapy" to treat relapsed, aggressive non-Hodgkin's lymphoma, cmte. says. Partial responses seen in the pivotal trial of the liposomal vincristine treatment are not reasonably likely to predict a clinical benefit, cmte. finds.